Manage Tickers Link Financial Account

Has my stock been accused of fraud?Join over 160k users who know.

Ticker	Price	Change($)	Change(%)	Shares	Volume	Prev Close	Open	Gain($)	Gain(%)

Ticker	Status	Jurisdiction	Filing Date	CP Start	CP End	CP Loss	Deadline

Ticker	Case Name	Status	CP Start	CP End	Deadline	Settlement Amt

Ticker	Name	Date	Analyst Firm	Up/Down	Target ($)	Rating Change	Rating Current

ARS Pharmaceuticals Announced The Publication Of Its Full Pharmacokinetic And Pharmacodynamic Results From One Of Its Four Primary Registration Studies Of Neffy In The Journal Of Allergy And Clinical Immunology

Author: Benzinga Newsdesk | October 03, 2023 09:06am

neffy resulted in robust responses on pharmacodynamic (PD) surrogates of efficacy observed even at 1 minute after dosing, and which were comparable to, or greater in magnitude than, EpiPen
Repeat doses of neffy resulted in statistically greater mean maximum responses on PD surrogates for efficacy compared to EpiPen
Repeat doses of neffy resulted in dose-proportional pharmacokinetic (PK) exposures, unlike injection, which results in less than proportional PK exposure with repeat doses

Posted In: SPRY